Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

Open access
Fiona Turnbull · 2003 · The Lancet

Abstract

Background The benefits of reducing blood pressure on the risks of major cardiovascular disease are well established, but uncertainty remains about the comparative effects of different blood-pressure-lowering regimens. We aimed to estimate effects of strategies based on different drug classes (angiotensin-converting-enzyme [ACE] inhibitors, calcium antagonists, angiotensin-receptor blockers [ARBs], and diuretics or beta blockers) or those targeting different blood pressure goals, on the risks of major cardiovascular events and death.Methods We did seven sets of prospectively-designed overviews with data from 29 randomised trials (n=162341). The trial eligibility criteria, primary outcomes, and main hypotheses were specified before the result of any contributing trial was known.Findings In placebo-controlled trials the relative risks of total major cardiovascular events were reduced by regimens based on ACE inhibitors (22%; 95% CI 17-27) or calcium antagonists (18%; 5-29). Greater risk reductions were produced by regimens that targeted lower blood pressure goals (15%; 5-24). ARB-based regimens reduced the risks of total major cardiovascular events (10%; 4-17) compared with control regimens. There were no significant differences in total major cardiovascular events between regimens based on ACE inhibitors, calcium antagonists, or diuretics or beta blockers, although ACE-inhibitor-based regimens reduced blood pressure less. There was evidence of some differences between active regimens in their effects on cause-specific outcomes. For every outcome other than heart failure, the difference between randomised groups in achieved blood pressure reduction was directly related to the observed difference in risk.Interpretation Treatment with any commonly-used regimen reduces the risk of total major cardiovascular events, and larger reductions in blood pressure produce larger reductions in risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(03)14739-3

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Research works printed but not linked: 2

  1. Yui, 2002, Long-term effects of nifedipine retardvs ACE inhibitors in hypertension with coronary heart disease: final report of JMIC-B, Circ J, 66, 357
  2. Cohn, 1995, Effect of felodipine on short-term exercise and neurohormone and long-term mortality in heart failure: results of V-Heft III, Circulation, 92, 1

Cited by

See all 2,402

Metadata

Authors
Turnbull, F.
Affiliations
The University of Sydney (AU)
Corresponding author
Fiona Turnbull
Venue
The Lancet
Publisher
Elsevier BV
Published
2003-11
Volume
362
Issue
9395
Pages
1527-1535
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W1497461844
Cited by
2,402
References
56
Citations by year
2026: 17 · 2025: 27 · 2024: 35 · 2023: 46 · 2022: 50 · 2021: 59 · 2020: 50 · 2019: 63 · 2018: 61 · 2017: 89 · 2016: 83 · 2015: 109 · 2014: 136 · 2013: 111 · 2012: 154
FWCI
96.54
Type
journal article
Language
en
Open access
Licence
  • other-oa
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Lirias (KU Leuven) (submittedVersion, other-oa)
Funders
  • Pfizer
  • Bayer
  • National Heart Foundation of Australia
  • Servier
  • Medical Research Council
  • National Health and Medical Research Council
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
Keywords
blood pressure reduction, antihypertensive regimens, major cardiovascular events, ACE inhibitors, calcium channel blockers, angiotensin receptor blockers, diuretics, beta-blockers, blood pressure targets, cardiovascular mortality, heart failure, antihypertensive therapy
MeSH terms
Adrenergic beta-Antagonists, Aged, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Calcium Channel Blockers, Cardiovascular Diseases, Diuretics, Female, Heart Failure, Humans, Hypertension, Male, Middle Aged, Placebos, Prospective Studies, Randomized Controlled Trials as Topic, Treatment Outcome, Risk Assessment, Angiotensin Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. https://app.cochat.ai/papers/10.1016/s0140-6736(03)14739-3
The paper
Turnbull, F. (2003). Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. The Lancet. https://doi.org/10.1016/s0140-6736(03)14739-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.